High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
Sophie JessopN Fuentos-BolanosC MayohM E M DolmanG TaxM Wong-ErasmusP AjuyahV TyrellG M MarshallD S ZieglerL M S LauPublished in: Cancer reports (Hoboken, N.J.) (2024)
This case report demonstrates the feasibility and role of combination pre-clinical high throughput screening to aid decision making in high-risk leukaemia. It also demonstrates the role a JAK1/2 inhibitor can have in the palliative setting in select patients with AML.